Tumor-specific neoantigen–Human Leukocyte Antigen complex (TSNA-HLA complex)

Tumor-specific neoantigen–Human Leukocyte Antigen (HLA) complexes are molecular structures formed when mutated proteins, unique to cancer cells, are processed into short peptides and displayed on the cell surface by HLA molecules (NCI Dictionary, 2024). These complexes serve as critical signals for the immune system, allowing T-cells to distinguish malignant cells from healthy tissue via T-cell receptor (TCR) recognition (Schumacher & Schreiber, Science, 2015). Because neoantigens arise from somatic mutations—such as single nucleotide variants, insertions/deletions, or gene fusions—they are not expressed in normal tissues, making them highly specific targets for immunotherapy with minimal risk of off-target effects on healthy cells (Blass & Ott, Nature Reviews Clinical Oncology, 2021). Therapeutic strategies leveraging these complexes include personalized neoantigen vaccines, which prime the immune system to recognize these specific markers, and adoptive T-cell therapies, such as TCR-engineered T-cells (TCR-T) designed to bind specific neoantigen-HLA pairs. Despite their potential, challenges include the high degree of patient-specific heterogeneity, the necessity for precise HLA matching, and the risk of tumor immune escape through HLA downregulation or defects in the antigen processing machinery (Sahin & Türeci, Science, 2018).

Other names

Neoantigen-HLA complexTumor-specific antigen-HLA complexNeoepitope-HLA complexpHLA complexMutant peptide-MHC complexNeoantigen-MHC complex

The complex acts as a specific ligand for T-cell receptors (TCRs); therapeutic interventions such as neoantigen vaccines or TCR-engineered T-cells (TCR-T) work by inducing or providing a population of T-cells that specifically recognize the mutated peptide sequence presented by the HLA molecule, leading to the targeted destruction of tumor cells (Schumacher & Schreiber, Science, 2015; Blass & Ott, Nature Reviews Clinical Oncology, 2021).